Autolus Therapeutics Ownership 2024 | Who Owns Autolus Therapeutics Now?
Institutional Ownership
77.80%
Insider Ownership
18.03%
Retail Ownership
4.17%
Institutional Holders
103.00
Autolus Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 9.61% | 86.51% | 21,346,829 | - | - | 74,286,965 | Jun 30, 2024 |
| BLACKSTONE INC. | 9.22% | 0.30% | 20,485,611 | - | - | 71,289,926 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 8.05% | 0.01% | 17,889,834 | 7,126,833 | 66.22% | 62,256,622 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 6.87% | 1.59% | 15,272,172 | - | - | 53,147,159 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 5.56% | 0.57% | 12,345,678 | - | - | 42,962,959 | Jun 30, 2024 |
| FMR LLC | 5.53% | 0.00% | 12,295,167 | 3,278,777 | 36.36% | 42,787,181 | Jun 30, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 3.60% | 6.94% | 8,000,000 | 474,318 | 6.30% | 27,840,000 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 2.81% | 0.27% | 6,250,000 | 1,578,000 | 33.78% | 21,750,000 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.08% | 0.75% | 4,623,324 | - | - | 16,089,168 | Jun 30, 2024 |
| BLACKROCK INC. | 2.00% | 0.00% | 4,436,102 | 380,182 | 9.37% | 15,437,635 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.99% | 0.00% | 4,414,087 | -1,074,899 | -19.58% | 15,362,000 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 1.72% | 4,300,000 | 925,000 | 27.41% | 14,964,000 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.64% | 0.15% | 3,646,230 | 1,555,759 | 74.42% | 12,688,881 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.64% | 0.21% | 3,639,000 | - | - | 12,663,720 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 1.55% | 2.29% | 3,441,667 | 2,275,000 | 195.00% | 11,977,001 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.44% | 0.02% | 3,200,000 | - | - | 11,136,000 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | 0.00% | 2,904,843 | 2,214,370 | 320.70% | 10,108,854 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 1.20% | 2.72% | 2,662,732 | -302,989 | -10.22% | 9,266,307 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 1.14% | 0.00% | 2,531,688 | 1,080,897 | 74.50% | 8,810,276 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1.10% | 0.01% | 2,452,040 | 779,308 | 46.59% | 8,533,099 | Jun 30, 2024 |
Autolus Therapeutics's largest institutional shareholder is SYNCONA PORTFOLIO LTD, holding 9.61% of the company's total share outstanding, currently valued at $74.29M. The top 10 institutional shareholders own together 55.34% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SYNCONA PORTFOLIO LTD | 9.61% | 86.51% | 21,346,829 | - | - | 74,286,965 | Jun 30, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 3.60% | 6.94% | 8,000,000 | 474,318 | 6.30% | 27,840,000 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 1.20% | 2.72% | 2,662,732 | -302,989 | -10.22% | 9,266,307 | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | 0.38% | 2.54% | 839,472 | 839,472 | 100.00% | 2,921,362 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 1.55% | 2.29% | 3,441,667 | 2,275,000 | 195.00% | 11,977,001 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 1.72% | 4,300,000 | 925,000 | 27.41% | 14,964,000 | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | 6.87% | 1.59% | 15,272,172 | - | - | 53,147,159 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.08% | 0.75% | 4,623,324 | - | - | 16,089,168 | Jun 30, 2024 |
| HIGHVISTA STRATEGIES LLC | 0.23% | 0.66% | 518,820 | 257,496 | 98.54% | 1,805,494 | Jun 30, 2024 |
| AVORO CAPITAL ADVISORS LLC | 5.56% | 0.57% | 12,345,678 | - | - | 42,962,959 | Jun 30, 2024 |
| HEALTHINVEST PARTNERS AB | 0.10% | 0.48% | 226,145 | 129,800 | 134.72% | 786,984 | Jun 30, 2024 |
| BLACKSTONE INC. | 9.22% | 0.30% | 20,485,611 | - | - | 71,289,926 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 0.16% | 0.29% | 346,667 | 130,000 | 60.00% | 1,206,401 | Jun 30, 2024 |
| COMMODORE CAPITAL LP | 0.53% | 0.28% | 1,178,723 | -1,121,277 | -48.75% | 4,101,956 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 2.81% | 0.27% | 6,250,000 | 1,578,000 | 33.78% | 21,750,000 | Jun 30, 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.64% | 0.21% | 3,639,000 | - | - | 12,663,720 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.64% | 0.15% | 3,646,230 | 1,555,759 | 74.42% | 12,688,881 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.28% | 0.15% | 610,902 | 610,902 | 100.00% | 2,125,939 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.07% | 0.14% | 160,639 | 110,581 | 220.91% | 542,960 | Jun 30, 2024 |
| ALPHABET INC. | 0.31% | 0.12% | 698,262 | - | - | 2,429,952 | Jun 30, 2024 |
The largest Autolus Therapeutics shareholder by % of total assets is SYNCONA PORTFOLIO LTD. The company owns 21.35M shares of Autolus Therapeutics (AUTL), representing 86.51% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 8.05% | 0.01% | 17,889,834 | 7,126,833 | 66.22% | 62,256,622 | Jun 30, 2024 |
| FMR LLC | 5.53% | 0.00% | 12,295,167 | 3,278,777 | 36.36% | 42,787,181 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 1.55% | 2.29% | 3,441,667 | 2,275,000 | 195.00% | 11,977,001 | Jun 30, 2024 |
| MORGAN STANLEY | 1.31% | 0.00% | 2,904,843 | 2,214,370 | 320.70% | 10,108,854 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 2.81% | 0.27% | 6,250,000 | 1,578,000 | 33.78% | 21,750,000 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 1.64% | 0.15% | 3,646,230 | 1,555,759 | 74.42% | 12,688,881 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 1.14% | 0.00% | 2,531,688 | 1,080,897 | 74.50% | 8,810,276 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 1.94% | 1.72% | 4,300,000 | 925,000 | 27.41% | 14,964,000 | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | 0.38% | 2.54% | 839,472 | 839,472 | 100.00% | 2,921,362 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.52% | 0.01% | 1,145,056 | 821,156 | 253.52% | 3,984,795 | Jun 30, 2024 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1.10% | 0.01% | 2,452,040 | 779,308 | 46.59% | 8,533,099 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.45% | 0.01% | 1,005,916 | 777,074 | 339.57% | 3,500,588 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.36% | 0.00% | 802,081 | 753,506 | 1551.22% | 2,791,242 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.28% | 0.15% | 610,902 | 610,902 | 100.00% | 2,125,939 | Jun 30, 2024 |
| STATE STREET CORP | 0.27% | 0.00% | 596,143 | 550,287 | 1200.03% | 2,074,578,000 | Jun 30, 2024 |
| TFG ASSET MANAGEMENT GP LTD | 3.60% | 6.94% | 8,000,000 | 474,318 | 6.30% | 27,840,000 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.37% | 0.00% | 813,031 | 432,503 | 113.66% | 2,829,348 | Jun 30, 2024 |
| JPMORGAN CHASE & CO | 0.24% | 0.00% | 523,700 | 394,791 | 306.26% | 1,822,476 | Jun 30, 2024 |
| BLACKROCK INC. | 2.00% | 0.00% | 4,436,102 | 380,182 | 9.37% | 15,437,635 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | 0.53% | 0.01% | 1,188,493 | 359,732 | 43.41% | 4,135,956 | Jun 30, 2024 |
As of Jun 30 2024, Autolus Therapeutics's largest institutional buyer is WELLINGTON MANAGEMENT GROUP LLP. The company purchased 7.13M stocks of AUTL, valued at $62.26M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | - | - | - | -6,616,667 | -100.00% | - | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | - | - | - | -6,425,803 | -100.00% | - | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | - | - | - | -4,330,745 | -100.00% | - | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | - | - | - | -1,390,160 | -100.00% | - | Jun 30, 2024 |
| FRED ALGER MANAGEMENT, LLC | 0.00% | 0.00% | 10,262 | -1,186,614 | -99.14% | 35,712 | Jun 30, 2024 |
| COMMODORE CAPITAL LP | 0.53% | 0.28% | 1,178,723 | -1,121,277 | -48.75% | 4,101,956 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.99% | 0.00% | 4,414,087 | -1,074,899 | -19.58% | 15,362,000 | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | - | - | - | -500,000 | -100.00% | - | Jun 30, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | - | - | - | -492,000 | -100.00% | - | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -429,152 | -100.00% | - | Jun 30, 2024 |
| NOMURA ASSET MANAGEMENT CO LTD | - | - | - | -384,796 | -100.00% | - | Jun 30, 2024 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.07% | 0.00% | 148,577 | -364,270 | -71.03% | 517,048 | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | 1.20% | 2.72% | 2,662,732 | -302,989 | -10.22% | 9,266,307 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 0.34% | 0.00% | 757,535 | -282,142 | -27.14% | 2,636,221 | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -279,820 | -100.00% | - | Jun 30, 2024 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | - | - | - | -273,929 | -100.00% | - | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | - | - | - | -250,000 | -100.00% | - | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | - | - | - | -205,225 | -100.00% | - | Jun 30, 2024 |
| LGT CAPITAL PARTNERS LTD. | 0.17% | 0.04% | 370,000 | -180,000 | -32.73% | 1,287,600 | Jun 30, 2024 |
| UBS OCONNOR LLC | - | - | - | -155,857 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Autolus Therapeutics's biggest institutional seller is CORMORANT ASSET MANAGEMENT, LP. The company sold -6.62M shares of AUTL, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EXOME ASSET MANAGEMENT LLC | 0.38% | 2.54% | 839,472 | 839,472 | 100.00% | 2,921,362 | Jun 30, 2024 |
| EVERSEPT PARTNERS, LP | 0.28% | 0.15% | 610,902 | 610,902 | 100.00% | 2,125,939 | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.12% | 0.06% | 266,692 | 266,692 | 100.00% | 928,088 | Jun 30, 2024 |
| VONTOBEL HOLDING LTD. | 0.09% | 0.00% | 207,097 | 207,097 | 100.00% | 720,698 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.04% | 0.00% | 99,319 | 99,319 | 100.00% | 345,630 | Jun 30, 2024 |
| CLEARSTEAD ADVISORS, LLC | 0.04% | 0.01% | 96,107 | 96,107 | 100.00% | 334,453 | Jun 30, 2024 |
| MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 0.03% | 0.00% | 74,398 | 74,398 | 100.00% | 258,905 | Jun 30, 2024 |
| LEGAL & GENERAL GROUP PLC | 0.03% | - | 60,512 | 60,512 | 100.00% | 210,885 | Jun 30, 2024 |
| HANDELSBANKEN FONDER AB | 0.03% | 0.00% | 56,000 | 56,000 | 100.00% | 195,000 | Jun 30, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | 0.01% | 0.01% | 27,395 | 27,395 | 100.00% | 95,000 | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | 0.01% | 0.00% | 20,589 | 20,589 | 100.00% | 71,650 | Jun 30, 2024 |
| VIRTUS ETF ADVISERS LLC | 0.01% | 0.03% | 19,984 | 19,984 | 100.00% | 69,544 | Jun 30, 2024 |
| PROSHARE ADVISORS LLC | 0.01% | 0.00% | 12,313 | 12,313 | 100.00% | 42,849 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.00% | 0.00% | 5,955 | 5,955 | 100.00% | 19,830 | Jun 30, 2024 |
| ITAU UNIBANCO HOLDING S.A. | 0.00% | 0.00% | 3,763 | 3,763 | 100.00% | 13,095 | Jun 30, 2024 |
Autolus Therapeutics's largest new institutional shareholder by number of shares is EXOME ASSET MANAGEMENT LLC, purchased 839.47K shares, valued at $2.92M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | - | - | - | -6,616,667 | -100.00% | - | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | - | - | - | -6,425,803 | -100.00% | - | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | - | - | - | -4,330,745 | -100.00% | - | Jun 30, 2024 |
| LYNX1 CAPITAL MANAGEMENT LP | - | - | - | -1,390,160 | -100.00% | - | Jun 30, 2024 |
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | - | - | - | -500,000 | -100.00% | - | Jun 30, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | - | - | - | -492,000 | -100.00% | - | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -429,152 | -100.00% | - | Jun 30, 2024 |
| NOMURA ASSET MANAGEMENT CO LTD | - | - | - | -384,796 | -100.00% | - | Jun 30, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | - | - | - | -279,820 | -100.00% | - | Jun 30, 2024 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | - | - | - | -273,929 | -100.00% | - | Jun 30, 2024 |
| STEMPOINT CAPITAL LP | - | - | - | -250,000 | -100.00% | - | Jun 30, 2024 |
| VOYA INVESTMENT MANAGEMENT LLC | - | - | - | -205,225 | -100.00% | - | Jun 30, 2024 |
| UBS OCONNOR LLC | - | - | - | -155,857 | -100.00% | - | Jun 30, 2024 |
| EAM GLOBAL INVESTORS LLC | - | - | - | -118,721 | -100.00% | - | Jun 30, 2024 |
| CAPSTONE INVESTMENT ADVISORS, LLC | - | - | - | -79,374 | -100.00% | - | Jun 30, 2024 |
| ENVESTNET ASSET MANAGEMENT INC | - | - | - | -41,812 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -37,300 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -21,540 | -100.00% | - | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | - | - | - | -20,100 | -100.00% | - | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | - | - | - | -16,692 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -7,417 | -100.00% | - | Jun 30, 2024 |
| AQUATIC CAPITAL MANAGEMENT LLC | - | - | - | -3,100 | -100.00% | - | Jun 30, 2024 |
| CARMICHAEL HILL & ASSOCIATES, INC. | - | - | - | -254 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -160 | -100.00% | - | Jun 30, 2024 |
Autolus Therapeutics's largest sold out institutional shareholder by shares sold is CORMORANT ASSET MANAGEMENT, LP, sold -6.62M shares, valued at -, as of undefined.
Autolus Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Alger ETF Trust | 6.46% | 45,861 | 45,861 | - | Dec 31, 2023 |
| ALGER INSTITUTIONAL FUNDS | 0.49% | 126,568 | 126,568 | - | Jan 31, 2024 |
| T. Rowe Price New Horizons Fund, Inc. | 0.46% | 2,282,116 | 1,182,869 | 107.61% | Mar 31, 2024 |
| ALGER PORTFOLIOS | 0.43% | 159,816 | 159,816 | - | Dec 31, 2023 |
| ALGER FUNDS | 0.34% | 323,215 | 323,215 | - | Jan 31, 2024 |
| ALGER FUNDS II | 0.31% | 69,091 | 69,091 | - | Jan 31, 2024 |
| BlackRock Health Sciences Trust II | 0.29% | 765,897 | 303,786 | 65.74% | Mar 31, 2024 |
| BlackRock Health Sciences Trust | 0.25% | 64,258 | 64,258 | - | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES VII | 0.12% | 996,000 | - | - | Jan 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.07% | 230,858 | - | - | Mar 31, 2024 |
| BNY MELLON VARIABLE INVESTMENT FUND | 0.05% | 12,322 | 12,322 | - | Mar 31, 2024 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.03% | 101,096 | - | - | Mar 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.02% | 192,827 | - | - | Jan 31, 2024 |
| ETFis Series Trust I | 0.02% | 27,536 | - | - | Jan 31, 2024 |
| Harbor ETF Trust | 0.01% | 64,128 | -30,988 | -32.58% | Jan 31, 2024 |
| ALPS ETF Trust | 0.01% | 122,678 | - | - | Feb 29, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.01% | 86,372 | 86,372 | - | Mar 28, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 618,833 | 238,648 | 62.77% | Feb 29, 2024 |
| SMALLCAP WORLD FUND INC | 0.01% | 625,000 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.01% | 11,178 | - | - | Mar 31, 2024 |
| HARBOR FUNDS | 0.01% | 150,589 | -80,172 | -34.74% | Jan 31, 2024 |
| FORUM FUNDS II | 0.01% | 6,402 | - | - | Jan 31, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.00% | 53,650 | - | - | Mar 31, 2024 |
| Destra Investment Trust | 0.00% | 6,606 | - | - | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 90,050 | 11,850 | 15.15% | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 57,474 | 9,211 | 19.09% | Feb 29, 2024 |
| JOHCM Funds Trust | 0.00% | 23,110 | -19,969 | -46.35% | Mar 28, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 311,437 | 276,351 | 787.64% | Jan 31, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 47,398 | 47,398 | - | Mar 31, 2024 |
| BlackRock ETF Trust | 0.00% | 949 | 949 | - | Jan 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 3,351 | - | - | Feb 29, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 44,108 | 44,108 | - | Feb 29, 2024 |
| RBB FUND, INC. | 0.00% | 48,359 | 48,359 | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 86,256 | - | - | Feb 29, 2024 |
| Fidelity Rutland Square Trust II | 0.00% | 398,650 | 398,650 | - | Feb 29, 2024 |
| Weiss Strategic Interval Fund | 0.00% | 907 | 907 | - | Sep 30, 2022 |
| SPDR INDEX SHARES FUNDS | 0.00% | 45,856 | -6,531 | -12.47% | Mar 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 889,962 | 889,962 | - | Feb 29, 2024 |
| VALIC Co I | 0.00% | 36,451 | 21,983 | 151.94% | Feb 29, 2024 |
| iSHARES TRUST | 0.00% | 1,245,435 | 435,159 | 53.71% | Mar 31, 2024 |
| TRUST FOR PROFESSIONAL MANAGERS | 0.00% | 21,311 | 21,311 | - | Feb 29, 2024 |
| Series Portfolios Trust | 0.00% | 353 | - | - | Jan 31, 2024 |
| PROSHARES TRUST | 0.00% | 10,501 | 5,635 | 115.80% | Feb 29, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 12,642 | - | - | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 11,490 | 1,054 | 10.10% | Feb 29, 2024 |
| EQ ADVISORS TRUST | 0.00% | 26,811 | 17,149 | 177.49% | Mar 31, 2024 |
| LoCorr Investment Trust | 0.00% | 550 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 38,928 | 25,116 | 181.84% | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 43,998 | 43,998 | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 5,472 | 3,326 | 154.99% | Dec 31, 2023 |
| John Hancock Funds II | 0.00% | 38,774 | 38,774 | - | Feb 29, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 200 | - | - | Mar 31, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 887 | - | - | Dec 31, 2023 |
Autolus Therapeutics's largest mutual fund holder by % of total assets is "Alger ETF Trust", owning 45.86K shares, compromising 6.46% of its total assets.
Autolus Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 103 | -14.88% |
| 31 Mar, 24 | 121 | 23.47% |
| 31 Dec, 23 | 98 | 42.03% |
| 30 Sep, 23 | 69 | - |
| 30 Jun, 23 | 69 | 6.15% |
| 31 Mar, 23 | 65 | -8.45% |
| 31 Dec, 22 | 71 | 12.70% |
| 30 Sep, 22 | 63 | -1.56% |
| 30 Jun, 22 | 64 | 1.59% |
| 31 Mar, 22 | 63 | -11.27% |
| 31 Dec, 21 | 71 | 18.33% |
| 30 Sep, 21 | 60 | -4.76% |
| 30 Jun, 21 | 63 | 3.28% |
| 31 Mar, 21 | 61 | 29.79% |
| 31 Dec, 20 | 47 | 2.17% |
| 30 Sep, 20 | 46 | -8.00% |
| 30 Jun, 20 | 50 | -1.96% |
| 31 Mar, 20 | 51 | -7.27% |
| 31 Dec, 19 | 55 | 25.00% |
| 30 Sep, 19 | 44 | -6.38% |
| 30 Jun, 19 | 47 | 30.56% |
| 31 Mar, 19 | 36 | -5.26% |
| 31 Dec, 18 | 38 | -2.56% |
| 30 Sep, 18 | 39 | -22.00% |
| 30 Jun, 18 | 50 | - |
As of 30 Jun 24, 103 institutions are holding Autolus Therapeutics's shares, representing a decrease of -14.88% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 172,855,681 | -1.42% |
| 31 Mar, 24 | 175,349,129 | 51.63% |
| 31 Dec, 23 | 115,642,954 | 4.62% |
| 30 Sep, 23 | 110,531,704 | 1.28% |
| 30 Jun, 23 | 109,136,054 | 3.18% |
| 31 Mar, 23 | 105,767,648 | -0.84% |
| 31 Dec, 22 | 106,659,881 | 116.58% |
| 30 Sep, 22 | 49,247,836 | -2.89% |
| 30 Jun, 22 | 50,712,235 | -4.39% |
| 31 Mar, 22 | 53,040,341 | 1.46% |
| 31 Dec, 21 | 52,276,893 | 110.31% |
| 30 Sep, 21 | 24,856,956 | -1.34% |
| 30 Jun, 21 | 25,195,749 | 12.47% |
| 31 Mar, 21 | 22,402,923 | 77.86% |
| 31 Dec, 20 | 12,596,157 | -0.38% |
| 30 Sep, 20 | 12,644,809 | -11.75% |
| 30 Jun, 20 | 14,328,878 | -10.32% |
| 31 Mar, 20 | 15,977,842 | 19.02% |
| 31 Dec, 19 | 13,423,962 | -0.16% |
| 30 Sep, 19 | 13,445,027 | -37.26% |
| 30 Jun, 19 | 21,429,033 | 18.24% |
| 31 Mar, 19 | 18,123,353 | 6.68% |
| 31 Dec, 18 | 16,988,891 | -4.84% |
| 30 Sep, 18 | 17,853,091 | 98.15% |
| 30 Jun, 18 | 9,010,057 | - |
Autolus Therapeutics (AUTL) has 172.86M shares outstanding as of 30 Jun 24, down -1.42% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 77.80% | 1.25% |
| 31 Mar, 24 | 78.93% | 1.79% |
| 31 Dec, 23 | 66.48% | 1.65% |
| 30 Sep, 23 | 63.53% | 1.61% |
| 30 Jun, 23 | 62.77% | 1.70% |
| 31 Mar, 23 | 60.85% | 0.73% |
| 31 Dec, 22 | 91.02% | 3.11% |
| 30 Sep, 22 | 54.12% | 1.74% |
| 30 Jun, 22 | 55.77% | 1.64% |
| 31 Mar, 22 | 58.34% | 1.11% |
| 31 Dec, 21 | 72.52% | 6.24% |
| 30 Sep, 21 | 34.10% | 2.69% |
| 30 Jun, 21 | 35.57% | 2.76% |
| 31 Mar, 21 | 35.87% | 8.82% |
| 31 Dec, 20 | 20.17% | 3.42% |
| 30 Sep, 20 | 24.27% | 3.20% |
| 30 Jun, 20 | 27.53% | 2.68% |
| 31 Mar, 20 | 32.05% | 4.42% |
| 31 Dec, 19 | 26.92% | 2.95% |
| 30 Sep, 19 | 30.21% | 1.25% |
| 30 Jun, 19 | 49.14% | 2.33% |
| 31 Mar, 19 | 45.92% | 2.45% |
| 31 Dec, 18 | 43.28% | 2.09% |
| 30 Sep, 18 | 45.53% | 4.84% |
| 30 Jun, 18 | 30.66% | - |
As of 30 Jun 24, Autolus Therapeutics is held by 77.80% institutional shareholders, representing a 1.25% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 51 | -28.17% |
| 31 Mar, 24 | 71 | 36.54% |
| 31 Dec, 23 | 52 | 116.67% |
| 30 Sep, 23 | 24 | -29.41% |
| 30 Jun, 23 | 34 | 17.24% |
| 31 Mar, 23 | 29 | -29.27% |
| 31 Dec, 22 | 41 | 105.00% |
| 30 Sep, 22 | 20 | -20.00% |
| 30 Jun, 22 | 25 | -7.41% |
| 31 Mar, 22 | 27 | -34.15% |
| 31 Dec, 21 | 41 | 32.26% |
| 30 Sep, 21 | 31 | -27.91% |
| 30 Jun, 21 | 43 | 4.88% |
| 31 Mar, 21 | 41 | 95.24% |
| 31 Dec, 20 | 21 | 40.00% |
| 30 Sep, 20 | 15 | -25.00% |
| 30 Jun, 20 | 20 | -33.33% |
| 31 Mar, 20 | 30 | 3.45% |
| 31 Dec, 19 | 29 | 31.82% |
| 30 Sep, 19 | 22 | -40.54% |
| 30 Jun, 19 | 37 | 164.29% |
| 31 Mar, 19 | 14 | -17.65% |
| 31 Dec, 18 | 17 | -5.56% |
| 30 Sep, 18 | 18 | -64.00% |
| 30 Jun, 18 | 50 | - |
51 institutional shareholders have increased their position in AUTL stock as of 30 Jun 24 compared to 71 in the previous quarter (a -28.17% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 28 | 3.70% |
| 31 Mar, 24 | 27 | 28.57% |
| 31 Dec, 23 | 21 | -12.50% |
| 30 Sep, 23 | 24 | 71.43% |
| 30 Jun, 23 | 14 | 27.27% |
| 31 Mar, 23 | 11 | -8.33% |
| 31 Dec, 22 | 12 | -42.86% |
| 30 Sep, 22 | 21 | 10.53% |
| 30 Jun, 22 | 19 | -24.00% |
| 31 Mar, 22 | 25 | 56.25% |
| 31 Dec, 21 | 16 | 14.29% |
| 30 Sep, 21 | 14 | 27.27% |
| 30 Jun, 21 | 11 | 10.00% |
| 31 Mar, 21 | 10 | -41.18% |
| 31 Dec, 20 | 17 | -5.56% |
| 30 Sep, 20 | 18 | -14.29% |
| 30 Jun, 20 | 21 | 110.00% |
| 31 Mar, 20 | 10 | -28.57% |
| 31 Dec, 19 | 14 | 7.69% |
| 30 Sep, 19 | 13 | 116.67% |
| 30 Jun, 19 | 6 | -57.14% |
| 31 Mar, 19 | 14 | -22.22% |
| 31 Dec, 18 | 18 | 28.57% |
| 30 Sep, 18 | 14 | - |
| 30 Jun, 18 | - | - |
28 institutional shareholders have reduced their position in AUTL stock as of 30 Jun 24 compared to 27 in the previous quarter (a 3.70% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 103 | -14.88% | 172,855,681 | -1.42% | 77.80% | 1.25% | 51 | -28.17% | 28 | 3.70% |
| 31 Mar, 24 | 121 | 23.47% | 175,349,129 | 51.63% | 78.93% | 1.79% | 71 | 36.54% | 27 | 28.57% |
| 31 Dec, 23 | 98 | 42.03% | 115,642,954 | 4.62% | 66.48% | 1.65% | 52 | 116.67% | 21 | -12.50% |
| 30 Sep, 23 | 69 | - | 110,531,704 | 1.28% | 63.53% | 1.61% | 24 | -29.41% | 24 | 71.43% |
| 30 Jun, 23 | 69 | 6.15% | 109,136,054 | 3.18% | 62.77% | 1.70% | 34 | 17.24% | 14 | 27.27% |
| 31 Mar, 23 | 65 | -8.45% | 105,767,648 | -0.84% | 60.85% | 0.73% | 29 | -29.27% | 11 | -8.33% |
| 31 Dec, 22 | 71 | 12.70% | 106,659,881 | 116.58% | 91.02% | 3.11% | 41 | 105.00% | 12 | -42.86% |
| 30 Sep, 22 | 63 | -1.56% | 49,247,836 | -2.89% | 54.12% | 1.74% | 20 | -20.00% | 21 | 10.53% |
| 30 Jun, 22 | 64 | 1.59% | 50,712,235 | -4.39% | 55.77% | 1.64% | 25 | -7.41% | 19 | -24.00% |
| 31 Mar, 22 | 63 | -11.27% | 53,040,341 | 1.46% | 58.34% | 1.11% | 27 | -34.15% | 25 | 56.25% |
| 31 Dec, 21 | 71 | 18.33% | 52,276,893 | 110.31% | 72.52% | 6.24% | 41 | 32.26% | 16 | 14.29% |
| 30 Sep, 21 | 60 | -4.76% | 24,856,956 | -1.34% | 34.10% | 2.69% | 31 | -27.91% | 14 | 27.27% |
| 30 Jun, 21 | 63 | 3.28% | 25,195,749 | 12.47% | 35.57% | 2.76% | 43 | 4.88% | 11 | 10.00% |
| 31 Mar, 21 | 61 | 29.79% | 22,402,923 | 77.86% | 35.87% | 8.82% | 41 | 95.24% | 10 | -41.18% |
| 31 Dec, 20 | 47 | 2.17% | 12,596,157 | -0.38% | 20.17% | 3.42% | 21 | 40.00% | 17 | -5.56% |
| 30 Sep, 20 | 46 | -8.00% | 12,644,809 | -11.75% | 24.27% | 3.20% | 15 | -25.00% | 18 | -14.29% |
| 30 Jun, 20 | 50 | -1.96% | 14,328,878 | -10.32% | 27.53% | 2.68% | 20 | -33.33% | 21 | 110.00% |
| 31 Mar, 20 | 51 | -7.27% | 15,977,842 | 19.02% | 32.05% | 4.42% | 30 | 3.45% | 10 | -28.57% |
| 31 Dec, 19 | 55 | 25.00% | 13,423,962 | -0.16% | 26.92% | 2.95% | 29 | 31.82% | 14 | 7.69% |
| 30 Sep, 19 | 44 | -6.38% | 13,445,027 | -37.26% | 30.21% | 1.25% | 22 | -40.54% | 13 | 116.67% |
| 30 Jun, 19 | 47 | 30.56% | 21,429,033 | 18.24% | 49.14% | 2.33% | 37 | 164.29% | 6 | -57.14% |
| 31 Mar, 19 | 36 | -5.26% | 18,123,353 | 6.68% | 45.92% | 2.45% | 14 | -17.65% | 14 | -22.22% |
| 31 Dec, 18 | 38 | -2.56% | 16,988,891 | -4.84% | 43.28% | 2.09% | 17 | -5.56% | 18 | 28.57% |
| 30 Sep, 18 | 39 | -22.00% | 17,853,091 | 98.15% | 45.53% | 4.84% | 18 | -64.00% | 14 | - |
| 30 Jun, 18 | 50 | - | 9,010,057 | - | 30.66% | - | 50 | - | - | - |
Autolus Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| VECT | VectivBio Holding AG |
| IKNA | Ikena Oncology, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| MNOV | MediciNova, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
AUTL Ownership FAQ
Who Owns Autolus Therapeutics?
Autolus Therapeutics is owned by institutional shareholders (77.80%), insiders (18.03%), and public (4.17%). The largest institutional shareholder of Autolus Therapeutics is SYNCONA PORTFOLIO LTD (9.61% of total shares) and the top mutual fund owner is Alger ETF Trust (6.46% of total shares).
Who are the major institutional shareholders of Autolus Therapeutics?
Autolus Therapeutics's major institutional shareholders are SYNCONA PORTFOLIO LTD, BLACKSTONE INC., WELLINGTON MANAGEMENT GROUP LLP, DEEP TRACK CAPITAL, LP, and AVORO CAPITAL ADVISORS LLC. The top five shareholders own together 39.31% of the company's share outstanding.
How many Autolus Therapeutics shareholders are there?
As of Jun 2024, there are 103 institutional shareholders of Autolus Therapeutics.
What percentage of Autolus Therapeutics is owned by SYNCONA PORTFOLIO LTD?
SYNCONA PORTFOLIO LTD owns 21.35M shares of Autolus Therapeutics, representing 9.61% of the company's total shares outstanding, valued at $74.29M (as of Jun 2024).
What percentage of Autolus Therapeutics is owned by BLACKSTONE INC?
As of Jun 2024, BLACKSTONE INC holds 20.49M shares of Autolus Therapeutics (AUTL), compromising 9.22% of the company, valued at $71.29M.
What percentage of Autolus Therapeutics is owned by WELLINGTON MANAGEMENT GROUP LLP?
WELLINGTON MANAGEMENT GROUP LLP is the third largest holder of Autolus Therapeutics. The company owns 17.89M of the company's shares outstanding (worth $62.26M).